Table 2.
Baseline comparisons between frequencies of visit.
| HYPO_S group | HYPO_M group | p value | |
|---|---|---|---|
| Number, n (%) | 744 (88%) | 99 (12%) | |
| Age (year) | 70 ± 14 | 69 ± 15 | 0.365 |
| Female, n (%) | 347 (46.6) | 43 (43.4) | 0.548 |
| BMI (kg/m2) | 23.0 ± 3.7 | 22.5 ± 3.7 | 0.346 |
| Alcohol (binge), n (%) | 73 (9.8) | 15 (15.2) | 0.103 |
| Type 1 DM, n (%) | 16 (2.2) | 3 (3.0) | 0.480 |
| DM duration (year) | 8.0 (4-20) | 10.0 (2-20) | 0.573 |
| Medication, n (%) | |||
| Insulin | 358 (48.1) | 47 (47.5) | 0.904 |
| Sulfonylurea | 251 (33.7) | 39 (39.4) | 0.266 |
| Meglitinide | 40 (5.4) | 4 (4.0) | 0.575 |
| Metformin | 149 (20.0) | 16 (16.2) | 0.363 |
| DPP4i | 128 (17.2) | 11 (11.1) | 0.125 |
| SGLT2i | 2 (0.3) | 0 (0.0) | >0.999 |
| Thiazolidinediones | 15 (2.0) | 5 (5.1) | 0.074 |
| α-Glucosidase inhibitors | 7 (0.9) | 1 (1.0) | >0.999 |
| HbA1c (%) | 6.7 ± 1.4 | 6.7 ± 1.3 | 0.667 |
| BUN (mg/dL) | 24 (16-37) | 23 (16-33) | 0.525 |
| Cr (mg/dL) | 1.14 (0.80-2.23) | 1.22 (0.88-1.92) | 0.505 |
| eGFR (mL/min/1.73m2) | 55 (27-81) | 51 (32-75) | 0.763 |
| Total protein (g/dL) | 6.53 ± 0.81 | 6.62 ± 0.67 | 0.255 |
| Albumin (g/dL) | 3.63 ± 0.65 | 3.72 ± 0.59 | 0.186 |
| Sodium (mmol/L) | 138.25 ± 5.25 | 138.63 ± 4.54 | 0.499 |
| Potassium (mmol/L) | 4.25 ± 0.79 | 4.17 ± 0.61 | 0.289 |
| Cl (mmol/L) | 102.60 ± 5.88 | 103.63 ± 4.80 | 0.058 |
| Total bilirubin (mg/dL) | 0.4 (0.31-0.63) | 0.4 (0.28-0.54) | 0.020 |
| AST (IU/L) | 27 (21-39) | 25 (20-30) | 0.018 |
| ALT (IU/L) | 19 (14-29) | 18 (13-26) | 0.092 |
| CPK, n | 88 (52-165) | 89 (50-179) | 0.905 |
| LDH, n | 497 (411-622) | 457 (391-553) | 0.006 |
| Amylase (μL/dL) | 98 (69-135) | 106 (73-144) | 0.242 |
| Lipase (U/L) | 23 (12-47) | 28 (10-52) | 0.808 |
| PT_INR (INR) | 1.13 ± 0.42 | 1.03 ± 0.09 | <0.001 |
| hsCRP (mg/dL) | 0.24 (0.06-1.63) | 0.15 (0.04-1.03) | 0.062 |
| Platelet count (K/μL) | 221 ± 93 | 244 ± 75 | 0.008 |
| WBC count, n | 8.0 (6-11) | 8.0 (6-11) | 0.502 |
| ANC, n | 7.16 ± 4.06 | 6.56 ± 3.55 | 0.169 |
| RBC count, n | 3.72 (3.32-4.23) | 3.85 (3.50-4.10) | 0.215 |
| Hemoglobin (g/dL) | 11.6 ± 2.1 | 11.87 ± 1.84 | 0.224 |
| Hematocrit (M/μL) | 34.4 ± 5.9 | 35.2 ± 5.1 | 0.188 |
| ALP (IU/L) | 73 (55-123) | 60 (45-89) | 0.059 |
| Gamma-GTP (IU/L) | 31 (17-110) | 26 (17-37) | 0.086 |
| TC (mg/dL) | 144.93 ± 45.88 | 157.50 ± 18.38 | 0.519 |
| TG (mg/dL) | 73 (53-98) | 86 (56-136) | 0.557 |
| HDL (mg/dL) | 39.39 ± 15.19 | 49.20 ± 9.26 | 0.180 |
| LDL (mg/dL) | 87.78 ± 41.74 | 80.67 ± 19.50 | 0.776 |
| Osmolality (mOsm/kg) | 295 ± 16 | 292 ± 18 | 0.259 |
| Comorbidity, n (%) | |||
| Ischemic heart disease | 194 (26.1) | 25 (25.3) | 0.861 |
| Cerebrovascular disease | 178 (23.9) | 24 (24.2) | 0.945 |
| Hypertensive disease | 162 (21.8) | 23 (23.2) | 0.742 |
| Aneurysm | 136 (18.3) | 23 (23.2) | 0.237 |
| Heart failure | 53 (7.1) | 4 (4.0) | 0.251 |
| Renal failure | 15 (2.0) | 2 (2.0) | >0.999 |
| Sudden cardiac death | 1 (0.1) | 0 (0.0) | >0.999 |
| Cancer | 124 (16.7) | 6 (6.1) | 0.006 |
BMI: body mass index; BUN: blood urea nitrogen; DM: diabetes mellitus; DPP4i: dipeptidyl peptidase-4 inhibitor; SGLT2i: sodium-glucose cotransporter 2 inhibitors; GFR: glomerular filtration rate.